Previous Close | 40.86 |
Open | 40.93 |
Bid | 40.29 x 800 |
Ask | 41.15 x 800 |
Day's Range | 40.32 - 40.96 |
52 Week Range | 29.85 - 45.00 |
Volume | |
Avg. Volume | 1,412,645 |
Market Cap | 5.129B |
Beta (5Y Monthly) | 1.25 |
PE Ratio (TTM) | 19.22 |
EPS (TTM) | 2.10 |
Earnings Date | May 07, 2024 - May 13, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 51.11 |
Halozyme Therapeutics Inc (NASDAQ:HALO), a biopharmaceutical company focused on developing and commercializing novel oncology therapies that target the tumor microenvironment, has reported an insider sell according to a recent SEC filing.
Artisan Partners, an investment management company, released its “Artisan Small Cap Fund” fourth quarter 2023 investor letter. A copy of the same can be downloaded here. The portfolio had a positive absolute return in Q4 but underperformed the Russell 2000 Growth Index due to security selection, particularly in the healthcare and information technology sectors. In the […]
Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to present and host investor meetings at the following investor conferences: